Summary

Human Metapneumovirus Diagnostics Market Growth and Trends

The global human metapneumovirus diagnostics market size is anticipated to reach USD 971.30 million by 2030 and is projected to grow at a CAGR 10.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. The human metapneumovirus (hMPV) diagnostics market is experiencing significant growth, driven by the increasing prevalence of respiratory infections caused by hMPV, particularly among vulnerable populations such as children, the elderly, and immunocompromised individuals. hMPV is known to cause respiratory illnesses similar to those caused by influenza and respiratory syncytial virus (RSV), including bronchiolitis, pneumonia, and upper respiratory tract infections. As awareness about hMPV’s role in respiratory diseases increases, there is a growing demand for effective diagnostic solutions, contributing to the market’s expansion.

Key drivers of this market include advancements in diagnostic technologies, rising healthcare spending, and the growing demand for early and accurate detection of hMPV infections. The increasing prevalence of viral respiratory infections, especially in regions with temperate climates, is also a significant factor propelling growth. Furthermore, the ongoing development of rapid diagnostic tests, such as PCR-based assays, antigen-based tests, and multiplex PCR platforms, enables faster detection, which is crucial for improving patient outcomes and controlling the spread of infections.

The hMPV diagnostics market is highly competitive, with several prominent players contributing to its growth. Key market participants include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, BioMérieux, and Siemens Healthineers. These companies are actively involved in developing new diagnostic tools and platforms to detect hMPV more efficiently. Strategic collaborations, acquisitions, and research and development investments are helping them expand their product portfolios and increase their presence.

Recent market trends highlight a shift towards more sophisticated, rapid, and cost-effective diagnostic methods, such as point-of-care testing and multiplex molecular tests that can detect multiple pathogens simultaneously. These innovations are critical in addressing the growing demand for efficient diagnostics, particularly in resource-limited settings. The market is also witnessing an increased focus on developing tests that provide faster results to aid in timely treatment decisions, which is essential for high-risk patient groups.

Prevalence rates of hMPV infections are rising globally, especially in children under five years of age, as well as in the elderly and those with weakened immune systems. The virus is responsible for a substantial number of respiratory hospitalizations, making it a significant public health concern. Accurate and timely diagnosis is crucial for effective management, and the growing adoption of diagnostic solutions is expected to continue to shape the future of the hMPV diagnostics market.

Human Metapneumovirus (hMPV) Diagnostics Market Report Highlights

• Based on technology, PCR-based diagnostics segment held the largest revenue share of 54.97% in 2024, driven by its high accuracy, sensitivity, and ability to detect low viral loads. PCR assays enable rapid, reliable detection of hMPV, even in early stages of infection, leading to faster diagnosis, better patient outcomes, and enhanced control of viral transmission, especially in high-risk populations.

• Based on end use, diagnostic and reference laboratories segment is expected to grow at the fastest CAGR over the forecast period driven by increasing demand for specialized testing, faster diagnostic results, and more accurate disease detection. These laboratories provide essential services for identifying hMPV and other respiratory infections, supporting both clinical and research settings.

• Based on region, North America market dominated the overall global market and accounted for the 41.18% revenue share in 2024 driven by the increasing due to higher awareness, advanced healthcare infrastructure, and increased prevalence of respiratory infections.

• The competitive scenario in the Human Metapneumovirus (hMPV) diagnostics market is high. The major companies are undertaking various strategies such as collaborations, new product development, mergers, acquisitions, and geographic expansion for serving the unmet needs of their customers.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Technology Segment
1.2.2. End-use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Global Human Metapneumovirus (hMPV) Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of respiratory infections
3.2.1.2. Advancements in molecular diagnostic
3.2.1.3. Growing awareness among healthcare providers
3.2.1.4. Supportive regulatory approvals and guidelines
3.2.2. Market Restraint Analysis
3.2.2.1. High costs of advanced diagnostics tests
3.2.2.2. Limited awareness in developing regions
3.3. Global Human Metapneumovirus (hMPV) Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Global Human Metapneumovirus (hMPV) Diagnostics Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Human Metapneumovirus (hMPV) Diagnostics Market Technology Movement Analysis
4.3. Global Human Metapneumovirus (hMPV) Diagnostics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. PCR-Based Diagnostics
4.4.1. PCR-based diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
4.5. Next-Generation Sequencing (NGS)
4.5.1. Next-Generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Million)
4.6. Immunofluorescence Assays
4.6.1. Immunofluorescence assays market estimates and forecast, 2018 - 2030 (USD Million)
4.7. Lateral Flow Assays
4.7.1. Lateral flow assays market estimates and forecast, 2018 - 2030 (USD Million)
4.8. Microarray Technology
4.8.1. Microarray technology market estimates and forecast, 2018 - 2030 (USD Million)
4.9. Other Advanced Technologies
4.9.1. Other advanced technologies market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5. Global Human Metapneumovirus (hMPV) Diagnostics Market: End-use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Human Metapneumovirus (hMPV) Diagnostics Market End-use Movement Analysis
5.3. Global Human Metapneumovirus (hMPV) Diagnostics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
5.4. Hospitals and Clinics
5.4.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Diagnostic and Reference Laboratories
5.5.1. Diagnostic and reference laboratories market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Academic and Research Institutions
5.6.1. Academic and research institutions market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Human Metapneumovirus (hMPV) Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. List of Key Certification Providers/Scheme Owners
7.5. Company Profiles/Listing
7.5.1. QuidelOrtho Corporation
7.5.1.1. Company overview
7.5.1.2. Financial performance
7.5.1.3. Product benchmarking
7.5.1.4. Strategic initiatives
7.5.2. ARUP Laboratories
7.5.2.1. Company overview
7.5.2.2. Financial performance
7.5.2.3. Product benchmarking
7.5.2.4. Strategic initiatives
7.5.3. Diasorin
7.5.3.1. Company overview
7.5.3.2. Financial performance
7.5.3.3. Product benchmarking
7.5.3.4. Strategic initiatives
7.5.4. R-Biopharm AG
7.5.4.1. Company overview
7.5.4.2. Financial performance
7.5.4.3. Product benchmarking
7.5.4.4. Strategic initiatives
7.5.5. Seegene Inc.
7.5.5.1. Company overview
7.5.5.2. Financial performance
7.5.5.3. Product benchmarking
7.5.5.4. Strategic initiatives
7.5.6. ZeptoMetrix
7.5.6.1. Company overview
7.5.6.2. Financial performance
7.5.6.3. Product benchmarking
7.5.6.4. Strategic initiatives
7.5.7. Abbott
7.5.7.1. Company overview
7.5.7.2. Financial performance
7.5.7.3. Product benchmarking
7.5.7.4. Strategic initiatives
7.5.8. Thermo Fisher Scientific Inc.
7.5.8.1. Company overview
7.5.8.2. Financial performance
7.5.8.3. Product benchmarking
7.5.8.4. Strategic initiatives